Oriola Oyj Valuation
Is OKDBV undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 4/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for OKDBV?
Other financial metrics that can be useful for relative valuation.
|What is OKDBV's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does OKDBV's PE Ratio compare to its peers?
|OKDBV PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
PIHLIS Pihlajalinna Oyj
TTALO Terveystalo Oyj
1345 China Pioneer Pharma Holdings
000705 Zhejiang Zhenyuan Share
OKDBV Oriola Oyj
Price-To-Earnings vs Peers: OKDBV is good value based on its Price-To-Earnings Ratio (17.9x) compared to the peer average (18.4x).
Price to Earnings Ratio vs Industry
How does OKDBV's PE Ratio compare vs other companies in the European Healthcare Industry?
Price-To-Earnings vs Industry: OKDBV is expensive based on its Price-To-Earnings Ratio (17.9x) compared to the European Healthcare industry average (14.1x)
Price to Earnings Ratio vs Fair Ratio
What is OKDBV's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||17.9x|
|Fair PE Ratio||17.3x|
Price-To-Earnings vs Fair Ratio: OKDBV is expensive based on its Price-To-Earnings Ratio (17.9x) compared to the estimated Fair Price-To-Earnings Ratio (17.3x).
Share Price vs Fair Value
What is the Fair Price of OKDBV when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: OKDBV (€1.8) is trading below our estimate of fair value (€3.42)
Significantly Below Fair Value: OKDBV is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.